CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade First Wave BioPharma, Inc. - FWBI CFD

3.1790
3.64%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.1420
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 3.299
Open* 3.419
1-Year Change* 33.89%
Day's Range* 3.149 - 3.419
52 wk Range 2.75-149.80
Average Volume (10 days) 270.89K
Average Volume (3 months) 14.15M
Market Cap 2.54M
P/E Ratio -100.00K
Shares Outstanding 675.00K
Revenue N/A
EPS -194.33
Dividend (Yield %) N/A
Beta 1.15
Next Earnings Date Mar 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 3.2990 -0.1500 -4.35% 3.4490 3.4490 3.2190
Apr 11, 2024 3.3390 -0.0600 -1.77% 3.3990 3.5290 3.2490
Apr 10, 2024 3.4090 -0.1900 -5.28% 3.5990 3.5990 3.3090
Apr 9, 2024 3.5090 -0.2200 -5.90% 3.7290 3.7290 3.4990
Apr 8, 2024 3.7490 -0.2000 -5.06% 3.9490 3.9490 3.6990
Apr 5, 2024 3.9490 -0.0200 -0.50% 3.9690 4.0190 3.8490
Apr 4, 2024 3.9790 0.0300 0.76% 3.9490 4.0590 3.9290
Apr 3, 2024 3.9490 -0.2300 -5.50% 4.1790 4.3590 3.9090
Apr 2, 2024 3.8990 -0.1800 -4.41% 4.0790 4.1390 3.8690
Apr 1, 2024 4.1590 -0.3800 -8.37% 4.5390 4.5390 3.9990
Mar 28, 2024 4.3890 0.4900 12.57% 3.8990 4.5190 3.8090
Mar 27, 2024 3.9090 -0.0900 -2.25% 3.9990 4.0590 3.8090
Mar 26, 2024 3.9590 -0.0400 -1.00% 3.9990 4.0690 3.8990
Mar 25, 2024 4.1190 -0.2800 -6.37% 4.3990 4.3990 3.9990
Mar 22, 2024 4.2490 -0.2400 -5.35% 4.4890 4.4890 4.2490
Mar 21, 2024 4.4190 -0.2100 -4.54% 4.6290 4.6290 4.2490
Mar 20, 2024 4.5190 -0.3400 -7.00% 4.8590 4.8990 4.3990
Mar 19, 2024 4.8490 0.1000 2.11% 4.7490 5.0590 4.7490
Mar 18, 2024 4.8790 0.2700 5.86% 4.6090 4.9490 4.3890
Mar 15, 2024 4.7790 -0.1600 -3.24% 4.9390 5.1990 4.6990

First Wave BioPharma, Inc. Events

Time (UTC) Country Event
Sunday, May 12, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 First Wave BioPharma Inc Earnings Release
Q1 2024 First Wave BioPharma Inc Earnings Release

Forecast

-

Previous

-
Friday, June 21, 2024

Time (UTC)

13:00

Country

US

Event

First Wave BioPharma Inc Annual Shareholders Meeting
First Wave BioPharma Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, August 14, 2024

Time (UTC)

20:00

Country

US

Event

Q2 2024 First Wave BioPharma Inc Earnings Release
Q2 2024 First Wave BioPharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 12.6781 59.0569 26.8313 14.7437 13.4318
Selling/General/Admin. Expenses, Total 11.9868 18.3696 7.27976 6.04227 8.17431
Research & Development 8.7763 38.3204 19.105 7.85849 4.98555
Depreciation / Amortization 0.015 0.048 0.84299 0.06191
Other Operating Expenses, Total -8.08505 0 0.21
Operating Income -12.6781 -59.0569 -26.8313 -14.7437 -13.4318
Interest Income (Expense), Net Non-Operating -0.00746 -0.01007 -5.84013 -0.43394 -0.10185
Other, Net -1.94411 0.5291
Net Income Before Taxes -14.6296 -58.5378 -32.6715 -15.1777 -13.5336
Net Income After Taxes -14.6296 -58.5378 -32.6715 -15.1777 -13.5336
Net Income Before Extra. Items -14.6296 -58.5378 -32.6715 -15.1777 -13.5336
Net Income -14.6296 -58.5378 -32.6715 -15.1777 -13.5336
Income Available to Common Excl. Extra. Items -14.9731 -84.5186 -41.7323 -15.1777 -13.5336
Income Available to Common Incl. Extra. Items -14.9731 -84.5186 -41.7323 -15.1777 -13.5336
Diluted Net Income -14.9731 -84.5186 -41.7323 -15.1777 -13.5336
Diluted Weighted Average Shares 0.71825 0.0425 0.01354 0.01068 0.00735
Diluted EPS Excluding Extraordinary Items -20.8466 -1988.67 -3082.15 -1421.4 -1840.94
Diluted Normalized EPS -20.8466 -1933.33 -3052.71 -1421.4 -1840.94
Revenue 0
Unusual Expense (Income) 0 2.35199 0.39857
Total Adjustments to Net Income -0.34343 -25.9807 -9.06087
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 4.18164 4.06243 2.27967 -4.38953 14.7879
Selling/General/Admin. Expenses, Total 2.82855 2.70074 2.17785 2.90445 6.90451
Research & Development 1.3531 1.36168 0.10182 0.79107 7.88341
Depreciation / Amortization
Operating Income -4.18164 -4.06243 -2.27967 4.38953 -14.7879
Interest Income (Expense), Net Non-Operating -0.00497 -0.00712 -0.0015 0.0018 -0.00775
Other, Net -0.00262 -0.00111 -1.70481 0 -0.2393
Net Income Before Taxes -4.18923 -4.07065 -3.98599 4.39133 -15.035
Net Income After Taxes -4.18923 -4.07065 -3.98599 4.39133 -15.035
Net Income Before Extra. Items -4.18923 -4.07065 -3.98599 4.39133 -15.035
Net Income -4.18923 -4.07065 -3.98599 4.39133 -15.035
Total Adjustments to Net Income -0.09432 -0.08743 0.00207 -0.15758 -0.18792
Income Available to Common Excl. Extra. Items -4.28356 -4.15808 -3.98392 4.23375 -15.2229
Income Available to Common Incl. Extra. Items -4.28356 -4.15808 -3.98392 4.23375 -15.2229
Diluted Net Income -4.28356 -4.15808 -3.98392 4.23375 -15.2229
Diluted Weighted Average Shares 2.27092 2.28068 0.71825 0.23225 0.18244
Diluted EPS Excluding Extraordinary Items -1.88626 -1.82318 -5.54671 18.2291 -83.4388
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.88626 -1.82318 -5.54671 18.2291 -83.4388
Unusual Expense (Income) 0
Other Operating Expenses, Total 0 0 -8.08505 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 3.41276 9.42495 7.86978 3.40829 4.8
Cash and Short Term Investments 1.36291 8.24868 6.06214 0.1758 1.11434
Cash 1.36291 8.24868 6.06214 0.1758 1.11434
Short Term Investments
Total Receivables, Net 0.09301 0 0.55149 2.6373 3.17268
Prepaid Expenses 1.95683 1.17627 1.25615 0.59519 0.51298
Total Assets 5.4397 11.79 12.9239 8.90288 7.4694
Property/Plant/Equipment, Total - Net 0.3031 0.40931 0.09257 0.15978 0.12885
Goodwill, Net 1.68418 1.91171 2.05405 1.88669 1.92483
Intangibles, Net 0 2.87954 3.40708 0.57048
Other Long Term Assets, Total 0.03966 0.04401 0.02792 0.04105 0.04523
Total Current Liabilities 2.48349 12.3004 15.5454 4.28564 2.99552
Payable/Accrued 0 0.53343 0.6701
Accrued Expenses 0.38633 0.49706 0.18443 0.15441 0.53829
Notes Payable/Short Term Debt 0.60349 0.64124 0.55241 1.5213 0.25503
Other Current Liabilities, Total 0.77363 8.48018 13.25 0.39299
Total Liabilities 2.69755 19.6115 15.5646 4.28564 2.99552
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.21406 7.31114 0.01912 0 0
Total Equity 2.74215 -7.82155 -2.64069 4.61724 4.47387
Common Stock 0.0001 0.00149 0.00312 0.00268 0.00177
Additional Paid-In Capital 171.276 147.305 93.8349 68.5759 53.1393
Retained Earnings (Accumulated Deficit) -168.534 -153.904 -95.3662 -62.6947 -47.5171
Other Equity, Total 0 -1.22414 -1.11255 -1.26656 -1.15011
Total Liabilities & Shareholders’ Equity 5.4397 11.79 12.9239 8.90288 7.4694
Total Common Shares Outstanding 0.995 0.07074 0.01483 0.01276 0.00843
Preferred Stock - Non Redeemable, Net 0 0 0 0
Property/Plant/Equipment, Total - Gross 0.34708 0.42402 0.13097 0.4233 0.33225
Accumulated Depreciation, Total -0.04398 -0.01471 -0.0384 -0.26352 -0.20339
Accounts Payable 0.72004 2.68191 1.55859 1.68351 1.53211
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 3.9766 2.35379 3.52987 3.41276 2.54914
Cash and Short Term Investments 3.29233 1.23605 2.06444 1.36291 1.65701
Cash 3.29233 1.23605 2.06444 1.36291 1.65701
Total Receivables, Net 0 0 0.02 0.09301 0.19198
Prepaid Expenses 0.68427 1.11774 1.44544 1.95683 0.56146
Total Assets 5.92727 4.32787 5.53398 5.4397 4.6454
Property/Plant/Equipment, Total - Net 0.23372 0.25713 0.28025 0.3031 0.32567
Property/Plant/Equipment, Total - Gross 0.29965 0.31575 0.33155 0.34708 0.36233
Accumulated Depreciation, Total -0.06593 -0.05862 -0.0513 -0.04398 -0.03666
Goodwill, Net 1.68418 1.68418 1.68418 1.68418 1.71479
Intangibles, Net
Other Long Term Assets, Total 0.03277 0.03277 0.03967 0.03966 0.0558
Total Current Liabilities 2.48249 3.26125 2.62486 2.48349 6.69416
Accounts Payable 0.57929 1.5912 0.46976 0.72004 3.58299
Accrued Expenses 0.89986 0.54343 0.91366 0.38633 0.33667
Notes Payable/Short Term Debt 0 0.15348 0.38039 0.60349 0
Other Current Liabilities, Total 1.00334 0.97315 0.86104 0.77363 2.77451
Total Liabilities 2.64846 3.44591 2.82138 2.69755 6.92545
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.16597 0.18466 0.19652 0.21406 0.23129
Total Equity 3.27881 0.88196 2.7126 2.74215 -2.28005
Common Stock 0.00135 0.00042 0.00016 0.0001 0.00023
Additional Paid-In Capital 183.505 177.675 175.317 171.276 163.722
Retained Earnings (Accumulated Deficit) -180.228 -176.794 -172.604 -168.534 -164.548
Other Equity, Total 0 -1.45472
Total Liabilities & Shareholders’ Equity 5.92727 4.32787 5.53398 5.4397 4.6454
Total Common Shares Outstanding 13.4635 4.209 1.54958 0.995 0.32958
Preferred Stock - Non Redeemable, Net
Other Current Assets, Total 0.13868
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -14.6296 -58.5378 -32.6715 -15.1777 -13.5336
Cash From Operating Activities -22.3441 -32.2882 -11.2215 -14.0335 -10.8693
Cash From Operating Activities 0.02927 0.01471 0.0378 0.0631 0.06191
Amortization 0 0.52755 0.52755 0.95695 0.73654
Non-Cash Items 2.75792 8.60641 6.73365 1.82513 3.57765
Changes in Working Capital -10.5016 17.101 14.1509 -1.70099 -1.7118
Cash From Investing Activities 0 -10.3195 0.08735 -0.0241 -0.30547
Capital Expenditures 0 -0.06949 -0.00417 -0.0241 -0.30547
Cash From Financing Activities 15.7395 44.7635 17.0461 13.145 11.7121
Financing Cash Flow Items -6.91496
Issuance (Retirement) of Stock, Net 23.2957 44.6747 14.1861 9.53834 11.9028
Issuance (Retirement) of Debt, Net -0.64124 0.08883 2.86003 3.60664 -0.19068
Foreign Exchange Effects -0.25971 0.03076 -0.02559 -0.02593 0.00354
Net Change in Cash -6.86426 2.18654 5.88635 -0.93855 0.54087
Cash Taxes Paid 0 0 0
Cash Interest Paid 0.01588 0 0.10546 0.00803 0.00401
Other Investing Cash Flow Items, Total 0 -10.25 0.09152
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.07065 -14.6296 -10.6437 -15.035 -9.62684
Cash From Operating Activities -2.84558 -22.3441 -16.7518 -12.4977 -7.91207
Cash From Operating Activities 0.00732 0.02927 0.02195 0.01464 0.00732
Amortization 0 0 0 0 0
Non-Cash Items 0.37384 2.75792 0.86545 0.75883 0.36042
Cash Interest Paid 0.00899 0.01588
Changes in Working Capital 0.84391 -10.5016 -6.99554 1.76384 1.34703
Cash From Investing Activities 0 0 0
Capital Expenditures 0 0 0
Cash From Financing Activities 3.54711 15.7395 10.2153 5.44352 5.36715
Financing Cash Flow Items 0 -6.91496 -5.05364 -2.41496 -2.41496
Issuance (Retirement) of Stock, Net 3.77021 23.2957 15.9102 8.3378 8.02057
Issuance (Retirement) of Debt, Net -0.2231 -0.64124 -0.64124 -0.47933 -0.23847
Foreign Exchange Effects 0 -0.25971 -0.03367 -0.03952 -0.00877
Net Change in Cash 0.70153 -6.86426 -6.57017 -7.09368 -2.5537
Cash Taxes Paid
Other Investing Cash Flow Items, Total 0 0 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

First Wave BioPharma, Inc. Company profile

About First Wave BioPharma Inc

First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.

Industry: Biotechnology & Medical Research (NEC)

777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

Gold

2,384.88 Price
+1.900% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.50

XRP/USD

0.50 Price
+1.330% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,121.61 Price
+0.800% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,718.50 Price
-1.550% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading